Novo Nordisk AS ADR NOVA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
GLP-1 drugs could ease back and knee pain, but doctors say there are risks for older adults
-
Novo Nordisk Says FDA Review of Hemophilia Drug Is Hitting Delays
-
Eli Lilly Says Zepbound Delivers Greater Weight Loss Than Higher-Dose Version of Novo's Wegovy
-
Taking Ozempic and worried about vision loss? This test can help you understand your risk.
-
Novo Nordisk strikes second licensing deal since frosty capital-markets day
-
Novo Inks Weight-Loss Licensing Deal With Hengrui Pharma
-
After capital-markets day flop, Novo strikes licensing deal that sends a Swedish company's stock soaring
-
Novo Nordisk to Pay Up to $1.3 Billion for Nanexa's Drug Delivery Technology
Trading Information
- Previous Close Price
- €33.94
- Day Range
- €33.64–34.48
- 52-Week Range
- —–—
- Bid/Ask
- €0.00 / €0.00
- Shares Outstanding
- 4.41B
- Market Cap
- $152.21B
- Volume/Avg
- 448 / —
Key Statistics
- Price/Earnings (Normalized)
- 8.92
- Price/Sales
- 3.48
- Dividend Yield (Trailing)
- 4.46%
- Dividend Yield (Forward)
- 4.46%
- Dividend Payment Schedule
- Apr, Aug
- Total Yield
- 4.98%
Company Profile
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Value
- Total Number of Employees
- 68,794
- Website
- https://www.novonordisk.com
Competitors
Valuation
|
Metric
|
NOVA
|
SNY
|
AZN
|
|---|---|---|---|
Price/Earnings (Normalized) | 8.92 | 11.38 | 14.67 |
Price/Book Value | 5.15 | 1.33 | 4.90 |
Price/Sales | 3.48 | 1.70 | 4.10 |
Price/Cash Flow | 8.33 | 7.04 | 16.22 |
Price/Earnings
NOVA
SNY
AZN
Financial Strength
|
Metric
|
NOVA
|
SNY
|
AZN
|
|---|---|---|---|
Quick Ratio | 0.64 | 0.49 | 0.66 |
Current Ratio | 0.87 | 0.99 | 0.89 |
Interest Coverage | — | 8.05 | 7.99 |
Quick Ratio
NOVA
SNY
AZN
Profitability
|
Metric
|
NOVA
|
SNY
|
AZN
|
|---|---|---|---|
Return on Assets (Normalized) | 21.31% | 7.96% | 9.00% |
Return on Equity (Normalized) | 59.99% | 14.96% | 21.69% |
Return on Invested Capital (Normalized) | 34.79% | 11.28% | 14.36% |
Return on Assets
NOVA
SNY
AZN
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|pywd<#P | LOCK|%@ | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|fW!&w$y | LOCK|m! | $630B | |||
| AbbVie Inc
ABBV
| LOCK|@@C&zw@ | LOCK|#N | $489B | |||
| Merck & Co Inc
MRK
| LOCK|!SP^&! | LOCK|&?$ | $359B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|rG!^B<? | LOCK|MDj | $344B | |||
| Novartis AG ADR
NVS
| LOCK|Vh@sV$ZR | LOCK|!Bs | $272B | |||
| AstraZeneca PLC
AZN
| LOCK|s>N&#JD< | LOCK|DN | $246B | |||
| Amgen Inc
AMGN
| LOCK|K@XM#DtH | LOCK|TSx | $224B | |||
| Gilead Sciences Inc
GILD
| LOCK|k^%bX#L | LOCK|W@? | $187B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|V%>>D!R | LOCK|>! | $169B |
United States